|
|
Volumn 293, Issue 5532, 2001, Pages 1049-1051
|
|
Responding to market failures in tuberculosis control
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMIKACIN;
AMINOSALICYLIC ACID;
CAPREOMYCIN;
CIPROFLOXACIN;
CYCLOSERINE;
ETHIONAMIDE;
ISONIAZID;
KANAMYCIN;
OFLOXACIN;
PROTIONAMIDE;
RIFAMPICIN;
TUBERCULOSTATIC AGENT;
ESSENTIAL DRUG;
TUBERCULOSIS;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
COST CONTROL;
DRUG COST;
DRUG MARKETING;
HEALTH CARE ACCESS;
HEALTH CARE COST;
HEALTH CARE POLICY;
HEALTH CARE QUALITY;
HEALTH ECONOMICS;
MULTIDRUG RESISTANCE;
PATENT;
PRIORITY JOURNAL;
SHORT SURVEY;
TREATMENT FAILURE;
TUBERCULOSIS CONTROL;
WORLD HEALTH ORGANIZATION;
ARTICLE;
DRUG INDUSTRY;
ECONOMICS;
HUMAN;
MANAGEMENT;
PILOT STUDY;
TUBERCULOSIS;
ANTITUBERCULAR AGENTS;
DRUG COSTS;
DRUG INDUSTRY;
DRUGS, ESSENTIAL;
HEALTH POLICY;
HUMANS;
PATENTS;
PILOT PROJECTS;
POLICY MAKING;
TUBERCULOSIS;
TUBERCULOSIS, MULTIDRUG-RESISTANT;
WORLD HEALTH ORGANIZATION;
|
|
EID: 0035839092
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.1061861 Document Type: Short Survey |
|
Times cited : (128)
|
|
References (27)
|
